Peptone was selected as one of Nature Biotechnology’s top academic spinouts in 2023
We are thrilled to announce that Peptone has been selected as one of the top academic startups by Nature Biotechnology in 2022. This recognition is a testament to our team’s hard work and dedication to developing cutting-edge technologies that address some of today’s most pressing challenges.
“Nature Biotechnology’s annual survey highlights academic start ups that are, among other things, correcting misfolded or disordered proteins, creating second-generation GPCR agonists, building a new gene delivery platform and mining cancer genomes for novel targets.”
Nature Biotechnology’s annual survey highlights academic startups that are making significant contributions to the fields of biotechnology and life sciences. Peptone was chosen for its innovative work on intrinsically disordered proteins (IDPs).
At Peptone, we are committed to advancing the frontiers of biotechnology and delivering solutions that have a positive impact on people’s lives. We are honored to be recognized by Nature Biotechnology and will continue to work tirelessly to bring our groundbreaking technologies to market.
We would like to thank our investors, partners, and supporters for their unwavering support. This recognition would not have been possible without their encouragement and belief in our mission. We look forward to continuing to work together to shape the future of biotechnology.
Eisenstein, M., Schmidt, C. & DeFrancesco, L. Nature Biotechnology’s academic spinouts 2022. Nat Biotechnol 41, 1669–1678 (2023). https://doi.org/10.1038/s41587-023-02023-z
Peptone is a translational biophysics company focused on the discovery of novel therapeutics against diseases driven by intrinsically disordered proteins. IDPs are proteins without a fixed structure that play a significant role in health and disease.